Boundless Bio Inc (BOLD) Stock Price, Quote & News

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 dem...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 766 9912

Website: boundlessbio.com

Address:

10955 Alexandria Way, Suite 100, San Diego, United States

THSSKS Mar. 20 at 1:53 PM

$BOLD this could easily 2-3X from here.

0 · Reply

Biotech_Pharma_Investor Mar. 20 at 8:15 AM

$BOLD This one is trading under the radar. Just 700+watchers in stockwits. Just 66 folowers in SeekingAlpha. Not much discussion in X.

0 · Reply

Biotech_Pharma_Investor Mar. 20 at 8:14 AM

$BOLD My coverage for anyone interested. Trading at 1/4 of cash with a very promising first-in-class ecDNA-targeting kinesin degrader and a runway to 2H 2028 https://seekingalpha.com/article/4884418-boundless-bio-an-underestimated-biotech-with-a-first-in-class-ecdna-targeted-kinesin-degrader

0 · Reply

OfficialStocktwitsUser Mar. 19 at 2:35 AM

$BOLD RSI: 52.38, MACD: -0.0060 Vol: 0.02, MA20: 1.15, MA50: 1.18 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

revuelto Mar. 18 at 8:07 PM

$BOLD initiated a position today ✌️

0 · Reply

Golibajje Mar. 14 at 1:54 AM

$BOLD One of the top among the worst biotech companies out there!! Surprised not a single lawsuit on them! Pipeline failure, no strategic direction.. hardly any progress.. yea!! milking the cash balance at ease!

1 · Reply

THSSKS Mar. 13 at 11:54 AM

$BOLD I’d like to see this liquidated or an activist pushing for strategic alternatives. Preferably Tang.

0 · Reply

vu_jade Mar. 9 at 6:12 PM

$BOLD $16 IPO lead by Goldman?

1 · Reply

TICKERTUTOR Mar. 5 at 3:21 PM

sold $ERAS and bought $BOLD

0 · Reply

BillionerOfKing Feb. 19 at 3:09 AM

$BOLD Current Stock Price: $1.16

0 · Reply

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Mar 9, 2026, 7:00 AM EDT - 12 days ago

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 4, 2026, 7:00 AM EST - 17 days ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 5, 2026, 7:00 AM EST - 6 weeks ago

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 20, 2026, 7:00 AM EST - 2 months ago

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Nov 24, 2025, 7:00 AM EST - 4 months ago

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 5, 2025, 7:00 AM EST - 4 months ago

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 13, 2025, 4:05 PM EDT - 5 months ago

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Jun 5, 2025, 4:58 PM EDT - 10 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 23, 2025, 4:01 PM EDT - 10 months ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

May 9, 2025, 7:00 AM EDT - 11 months ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Apr 3, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 26, 2025, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 3, 2025, 10:00 AM EST - 1 year ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Dec 12, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Announces Pipeline and Leadership Updates

Nov 25, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Nov 7, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 6, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Mar 27, 2024, 6:55 PM EDT - 2 years ago

Boundless Bio Announces Pricing of Initial Public Offering

THSSKS Mar. 20 at 1:53 PM

$BOLD this could easily 2-3X from here.

0 · Reply

Biotech_Pharma_Investor Mar. 20 at 8:15 AM

$BOLD This one is trading under the radar. Just 700+watchers in stockwits. Just 66 folowers in SeekingAlpha. Not much discussion in X.

0 · Reply

Biotech_Pharma_Investor Mar. 20 at 8:14 AM

0 · Reply

OfficialStocktwitsUser Mar. 19 at 2:35 AM

0 · Reply

revuelto Mar. 18 at 8:07 PM

$BOLD initiated a position today ✌️

0 · Reply

Golibajje Mar. 14 at 1:54 AM

1 · Reply

THSSKS Mar. 13 at 11:54 AM

$BOLD I’d like to see this liquidated or an activist pushing for strategic alternatives. Preferably Tang.

0 · Reply

vu_jade Mar. 9 at 6:12 PM

$BOLD $16 IPO lead by Goldman?

1 · Reply

TICKERTUTOR Mar. 5 at 3:21 PM

sold $ERAS and bought $BOLD

0 · Reply

BillionerOfKing Feb. 19 at 3:09 AM

$BOLD Current Stock Price: $1.16

0 · Reply

OfficialStocktwitsUser Feb. 18 at 3:52 AM

$BOLD RSI: 40.54, MACD: -0.0245 Vol: 0.06, MA20: 1.17, MA50: 1.19 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

vu_jade Feb. 17 at 8:34 PM

$BOLD undiscovered YOLO

0 · Reply

THSSKS Feb. 10 at 1:38 AM

$PLRX Either buyout coming or Tang going to force them to pivot once poison pill gone. In this now at $1.17, bought a little more to. Watching $BOLD as well but no position until it gets to plrx cash levels

2 · Reply

vu_jade Feb. 9 at 11:43 PM

$BOLD early days

0 · Reply

ChartCortex Feb. 9 at 3:12 PM

$BOLD Biotech or pharmaceutical; name suggests oncology focus.

0 · Reply

crookedtomlee Feb. 9 at 2:18 PM

$NEXN $COEP $TIVC $ZNB $BOLD

0 · Reply

SharkAttack1 Feb. 9 at 1:35 PM

$BOLD SEC disclosure that Fidelity own 12%

0 · Reply

topstockalerts Feb. 9 at 1:03 PM

Pre Market Top Gainers PT2 $NEXN $COEP $TIVC $ZNB $BOLD

0 · Reply

Getthismoney101 Feb. 2 at 5:08 PM

$BOLD drop and no news?

0 · Reply

theyellowbear Jan. 30 at 9:38 PM

$KOLD $BOLD new Fed chair nominee this morning who is not as dovish as expected, and the DXY was strongly rising. This is credited as one reason that Silver, Gold, risk assets sold off today. However, oil rose to highs, which is purportedly due to Iran risk also the BOIL started to risk later in the afternoon yesterday after falling on storage report (indicating storage is not an issue for price) but BOIL only rose in the last hours of the day in advance of the Iran situation this morning. So, I have to believe that after the Iran conflict is settled the March contract will return to $3.8

0 · Reply

OfficialStocktwitsUser Jan. 23 at 10:52 PM

$BOLD RSI: 55.88, MACD: 0.0145 Vol: 0.04, MA20: 1.24, MA50: 1.19 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StockBraker Jan. 22 at 9:41 PM

$KOLD $BOLD Two big mistakes I see people making here. 1. These are leveraged ETFs which means they decay over time. If prices were to stay flat both of these would lose money over time. These are not designed to be buy and hold. 2. You need to be looking at NG futures and further out. If you were watching the Feb Henry Hub at all you would see this. Chart below is from 5am to just now. Explore on your own - https://www.cmegroup.com/markets/energy/natural-gas/natural-gas.quotes.html

1 · Reply

Market Cap	26.66M
Revenue (ttm)	0.00
Net Income (ttm)	-58.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	124,700
Avg Vol	116,138
Day's Range	N/A - N/A
Shares Out	22.41M
Stochastic %K	75%
Beta	-0.98
Analysts	Hold
Price Target	$4.00